

Highlights of Continuing Medical Education Experience

Updated July 26, 2016

Activity Title:

Emerging Approaches in First-line Therapy for Metastatic Colorectal Cancer: Cleveland Clinic Tumor Board

Release Date: December 1, 2015

Expiration Date: November 30, 2015

Accreditation:

- Provided by Cleveland Clinic
- 1.25 AMA PRA Category 1 Credits(s)



Description:

An interactive online webcast focusing on current progress in the treatment of patients with non-small cell lung cancer. The multidisciplinary faculty present various aspects of a case, including management of crizotinib resistance in patients with ALK-positive disease, the role of ALK inhibitors for treatment, assessment of the proper radiation dose and potential toxicities associated with SBRT, and the methodology and current guidelines for ALK testing. Treatment of ALK-positive disease and use of stereotactic body radiotherapy in oligometastatic lung cancer are also presented.

Target Audience: This activity is designed for health care practitioners including medical and surgical oncologists, pathologists, pulmonologists, radiologists, surgeons, and other health care professionals who manage patients with lung cancer.

Outcomes (to-date):

- Level One: Participation
 - 999 HCPs participated in this activity
 - 541.50 AMA PRA Category 1 Credits claimed
- Level Three: 100% of learners achieved level three outcomes with a significant improvement in knowledge.

Activity Title:

Management of Locally Advanced HER2-Positive Breast Cancer

Release Date: March 11, 2015

Renewed: March 11, 2016

Expiration Date: March 10, 2017

Accreditation:

- Provided by Cleveland Clinic
- 1 AMA PRA Category 1 Credits(s)

Description:

This webcast provided expert insight on optimizing treatment of patients with HER2-positive early-stage/locally advanced breast cancer. It consists of a case presentation of a patient with HER2-

positive early-stage/locally advanced disease. Suggested treatment options based on best practices, current treatment guidelines, and data from relevant recent clinical trials is discussed. Expert faculty present various aspects of the case, including radiologic imaging, pathologic findings (particularly HER2 testing), and options for neoadjuvant therapy with HER2-targeted agents. Recommendations regarding surgical resection, options for adjuvant therapy with chemotherapy and targeted agents, and radiation therapy post-surgery are addressed.

Target Audience: This activity is designed for health care practitioners including medical oncologists, surgical oncologists and general surgeons, radiation oncologists, radiologists, pathologists, and other health care professionals who manage patients with breast cancer.

Outcomes (to-date):

- Level One: Participation
 - 1,782 HCPs participated in this activity
 - 610.75 AMA PRA Category 1 Credits claimed
- Level Three: 100% of learners achieved level three outcomes with a significant improvement in knowledge.



Activity Title:

ASCO University - Advanced Practitioner Certificate Programs

Release Date: March 16, 2016

Accreditation:

- AMA PRA Category 1 Credits(s) provided by The American Society of Clinical Oncology (ASCO)
- ANCC continuing nursing education credits provided by The Meniscus Educational Institute
- ACPE continuing pharmacy education credit provided by the Hematology Oncology Pharmacy Association (HOPA)



Description:

Three (3) certificate programs are tailored to the educational needs of Advanced Practitioners at specific points in their learning. All courses offer CME, Nursing, and Pharmacy credit and were developed in an educational partnership between the Association of Physician Assistants in Oncology (APAO), Advanced Practitioner Society for Hematology and Oncology (APSHO), American Society of Clinical Oncology (ASCO), Hematology/Oncology Pharmacy Association (HOPA), and Meniscus Educational Institute.

Target Audience: This activity is designed for health care practitioners including nurse practitioners, physician assistants, pharmacists, and clinical nurse specialists who manage patients with cancer.



Advanced Practitioner
Society for Hematology
and Oncology

Activity Title:

Collaborative Practice in the Management of Patients with Gastrointestinal and Pancreatic Neuroendocrine Tumors

Release Date: February 29, 2016

Expiration Date: February 28, 2017

Accreditation:

- Provided by Annenberg Center for Health Sciences at Eisenhower
 - 1 AMA PRA Category 1 Credits(s)
 - ANCC continuing nursing education credits
 - ACPE continuing pharmacy education credit



ANNENBERG CENTER FOR HEALTH SCIENCES
AT EISENHOWER

Description:

The therapeutic landscape for patients with neuroendocrine tumors (NETs) is rapidly changing. New medical therapies have recently been approved by the US Food and Drug Administration, while combination therapies, as well as a novel peptide imaging technique, are advancing through clinical trials. NETs are rare, so the typical oncologist or AP working in the community will not be familiar with their diagnosis and treatment. However, a wide and ever-changing variety of treatment modalities are used for patients with NETs, including surgery and cytotoxic chemotherapy. This session provides the advanced practitioners with evidence-based updates on the diagnosis and treatment of gastrointestinal and pancreatic neuroendocrine tumors.

Target Audience: The intended audience for this live conference is nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, hematology/oncology nurses, pharmacists, and physicians who specialize in the field of oncology.

Outcomes (to-date):

- Level One: Participation
 - 4,103 HCPs participated in this activity
 - 489 ANCC credits claimed
 - 2 AMA PRA Category 1 Credits claimed
 - 3 ACPE credits claimed
- Level Three: 100% of learners achieved level three outcomes with a significant improvement in knowledge.